ORIGINAL RESEARCH article
Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
This article is part of the Research TopicUbiquitination in Tumor Pathogenesis and Progression and its Therapeutic PotentialView all 6 articles
Identify and validate a novel ubiquitination-related biomarker for thyroid cancer prognosis and immunotherapy
Provisionally accepted
Yilin Li1Jutao Zeng1Xiongmeiyu Gong1
Wei Li1
Jueli Liu2Dan Li1Yangyan Zhong1Junjie Deng1
Deng Jian1Haigang Feng1Jie Luo1*
Hong Cao1*- 1The Second Affiliated Hospital,Hengyang Medical School,University of South China, Hengyang, China
- 2School of Medicine, Hunan Normal University, Changsha, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Ubiquitination is a critical protein modification process that plays a pivotal role in maintaining cellular homeostasis and is implicated in various pathophysiological processes, including thyroid cancer (THCA). Understanding the roles of ubiquitination-related genes in THCA progression and their interactions with the tumor microenvironment (TME) could provide valuable insights into prognosis and treatment strategies. Methods: Using iUUCD 2.0, ubiquitination-related genes were identified and subjected to consensus clustering on TCGA-THCA data. Differentially expressed genes (DEGs) between tumor and normal tissues were identified and used to construct a ubiquitination-related signature using Cox and LASSO regression. The signature's prognostic ability was validated using training and test datasets from TCGA. Immune cell infiltration, immunotherapy response, and drug sensitivity were analyzed. Results: Three ubiquitination clusters were identified among 454 genes. Four prognostic DEGs (F12, FBXO15, FBXW10, and USP44) formed the signature, significantly correlating with survival, immune cell infiltration, clinical characteristics, immune checkpoints, immunotherapy response, and drug sensitivity. Low-risk THCA patients had better prognosis and immunotherapy responses than high-risk patients. A stable nomogram combining the signature and clinical characteristics predicted patient survival. RT-qPCR and immunohistochemistry confirmed differential expression of key genes. Conclusion: Our study identifies and validates a novel four-gene ubiquitination-related signature as a promising and independent prognostic biomarker in THCA. Beyond outcome prediction, this signature demonstrates significant translational potential by accurately predicting immunotherapy responses, thereby facilitating the development of more personalized and effective treatment strategies for patients with THCA..
Keywords: thyroid cancer, Ubiquitination, Tumor Microenvironment, Immunotherapy, prognosis
Received: 10 Dec 2024; Accepted: 12 Dec 2025.
Copyright: © 2025 Li, Zeng, Gong, Li, Liu, Li, Zhong, Deng, Jian, Feng, Luo and Cao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jie Luo
Hong Cao
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.